Caxton Corp acquired a new position in shares of Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 13,074 shares of the biopharmaceutical company’s stock, valued at approximately $125,000. Dicerna Pharmaceuticals makes up about 0.1% of Caxton Corp’s investment portfolio, making the stock its 20th biggest holding.
Several other large investors have also recently made changes to their positions in DRNA. Cubist Systematic Strategies LLC acquired a new stake in shares of Dicerna Pharmaceuticals during the 1st quarter worth approximately $102,000. Quantitative Systematic Strategies LLC acquired a new stake in shares of Dicerna Pharmaceuticals during the 1st quarter worth approximately $113,000. Jane Street Group LLC acquired a new stake in shares of Dicerna Pharmaceuticals during the 1st quarter worth approximately $136,000. Verition Fund Management LLC acquired a new stake in shares of Dicerna Pharmaceuticals during the 1st quarter worth approximately $141,000. Finally, Endurant Capital Management LP acquired a new stake in shares of Dicerna Pharmaceuticals during the 4th quarter worth approximately $170,000. 77.28% of the stock is currently owned by institutional investors.
Shares of DRNA stock opened at $12.48 on Thursday. The firm has a market capitalization of $664.50 million, a P/E ratio of -3.41 and a beta of 2.34. Dicerna Pharmaceuticals Inc has a one year low of $2.69 and a one year high of $15.80.
Dicerna Pharmaceuticals (NASDAQ:DRNA) last announced its quarterly earnings results on Monday, May 14th. The biopharmaceutical company reported ($0.30) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.87) by $0.57. The business had revenue of $1.55 million for the quarter, compared to analyst estimates of $1.75 million. Dicerna Pharmaceuticals had a negative return on equity of 123.72% and a negative net margin of 1,665.11%. equities analysts forecast that Dicerna Pharmaceuticals Inc will post -1.35 earnings per share for the current year.
Several brokerages have recently weighed in on DRNA. BidaskClub lowered Dicerna Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, June 8th. Evercore ISI reissued an “outperform” rating and set a $17.00 price objective (up previously from $14.00) on shares of Dicerna Pharmaceuticals in a report on Friday, April 20th. ValuEngine raised Dicerna Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Wednesday, May 2nd. Cowen reissued a “buy” rating on shares of Dicerna Pharmaceuticals in a report on Tuesday, April 24th. Finally, HC Wainwright lowered Dicerna Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $12.00 price objective on the stock. in a report on Friday, March 23rd. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, four have given a buy rating and one has assigned a strong buy rating to the stock. Dicerna Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $12.88.
In related news, insider James B. Weissman sold 10,000 shares of the business’s stock in a transaction on Wednesday, May 9th. The stock was sold at an average price of $15.00, for a total value of $150,000.00. Following the sale, the insider now owns 19,800 shares of the company’s stock, valued at approximately $297,000. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider James B. Weissman sold 8,965 shares of the business’s stock in a transaction on Friday, April 20th. The shares were sold at an average price of $13.00, for a total value of $116,545.00. Following the completion of the sale, the insider now directly owns 9,800 shares in the company, valued at approximately $127,400. The disclosure for this sale can be found here. In the last ninety days, insiders sold 20,000 shares of company stock worth $280,000. 19.85% of the stock is owned by insiders.
Dicerna Pharmaceuticals Profile
Dicerna Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery and development of pharmaceuticals for the treatment of rare, viral infectious, chronic liver, and cardiovascular diseases. Its development programs include DCR-PHXC for the treatment of primary hyperoxaluria; DCR-HBVS for the treatment of chronic hepatitis B virus infection; and DCR-PCSK9 to treat hypercholesterolemia.
Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.